ERBB2 and cancer: Furthermore, it demonstrated that the cancer suppression dose of hertuzumab-VC-MMAE was significantly better than T-DM1, and the former was almost three times that of the latter; research on drug concentrations of total RC48-ADC and released MMAE in cancer tissues and serum showed that the RC48-ADC was targeting HER2 and released MMAE at the cancer site to maintain a steady concentration level for one week in HER2+ ovarian cancer models (Jiang et al., 2016).